2023 WCLC | ¸´ºêººÁØHÒ©ººË¹×´®ÁÛ×´·ÇСϸ°û·Î°©¹ú¼Ê¶àÖÐÑëIIIÆÚÁÙ´²Êý¾ÝÈëÑ¡¿ÚÍ·±¨¸æ
2023Äê9ÔÂ9ÈÕÖÁ12ÈÕ£¬Óɹú¼Ê·Î°©Ñо¿Ð»á£¨IASLC£©Ö÷ÀíµÄ2023ÄêÌìÏ·ΰ©´ó»á£¨World Conference on Lung Cancer, WCLC£©½«ÓÚмÓƾÙÐС£HÒ©ººË¹×´®£¨Ë¹Â³Àûµ¥¿¹£©ÍŽữÁÆÓÃÓÚÒ»ÏßÖÎÁƲ»¿ÉÊÖÊõÇгýµÄ¾Ö²¿ÍíÆÚ»òתÒÆÐÔÁÛ×´·ÇСϸ°û·Î°©£¨sqNSCLC£©µÄ×¢²áÐÔÁÙ´²ÊÔÑéASTRUM-004Ñо¿µÄÎÞÏ£ÍûÉúÑÄÆÚ£¨PFS£©¡¢×ÜÉúÑÄÆÚ£¨OS£©µÈÁÆЧºÍÇå¾²ÐÔµÄ×îÖÕÆÊÎöЧ¹û½«ÓÉǣͷÖ÷ÒªÑо¿Õß¡¢ÉϺ£ÊзοÆÒ½ÔºÖܲʴæ½ÌÊÚÒÔ¿ÚÍ·±¨¸æµÄÐÎʽÔڴ˴ξۻá»áÒéÉÏÊ×´ÎÐû²¼¡£
ASTRUM-004ΪһÏîÔÚ¼ÈÍùδ½ÓÊÜÖÎÁƵľֲ¿ÍíÆÚ»òתÒÆÐÔÁÛ×´·ÇСϸ°û·Î°©»¼ÕßÖнÏÁ¿HÒ©ÍŽữÁÆÓ뻯ÁÆÁ½×é¼äÁÙ´²ÁÆЧºÍÇå¾²ÐÔµÄËæ»ú¡¢Ë«Ã¤¡¢¹ú¼Ê¶àÖÐÑëIIIÆÚÑо¿£¬ÓÚÈ«Çò¶àµØ°üÀ¨Öйú¡¢Å·Ã˲¨À¼¡¢ÍÁ¶úÆäµÈ¹ú¼Ò¿ªÉèÑо¿ÖÐÑë²¢Èë×é537Àý»¼Õß¡£Ñо¿Ð§¹ûÏÔʾ£¬HÒ©ÏÔÖø¸ÄÉÆδ¾ÖÎÁƵľֲ¿ÍíÆÚ»òתÒÆÐÔsqNSCLC»¼ÕßµÄÉúÑÄÆÚ£¬ÇÒÇå¾²ÐÔ¿É¿Ø¡£»ùÓÚASTRUM-004Ñо¿Ð§¹û£¬HÒ©ÒÑÓÚ2022ÄêÕýʽ»ñµÃÖйúÒ©¼à¾ÖÅú×¼ÓÃÓÚÍŽữÁÆÒ»ÏßÖÎÁÆsqNSCLC¡£
HÒ© ººË¹×´®£¨Í¨ÓÃÃû£ºË¹Â³Àûµ¥¿¹×¢ÉäÒº£©ÊǸ´ºêººÁØÊ׸ö×ÔÖ÷Ñз¢µÄÁ¢ÒìÐͲúÆ·£¬Í¬Ê±Ò²ÊÇÈ«ÇòÊ׸ö»ñÅúÒ»ÏßÖÎÁÆСϸ°û·Î°©µÄ¿¹PD-1µ¥¿¹¡£×Ô2022Äê3ÔÂÕýʽ»ñÅúÉÏÊÐÒÔÀ´£¬HÒ©ÒÑÔÚÖйú»ñÅúÓÃÓÚÖÎÁÆ3Ïî˳Ӧ֢£¬°üÀ¨Î¢ÎÀÐǸ߶Ȳ»Îȹ̣¨MSI-H£©ÊµÌåÁö¡¢ÁÛ×´·ÇСϸ°û·Î°©£¨sqNSCLC£©ºÍÆÕ±éÆÚСϸ°û·Î°©£¨ES-SCLC£©£¬»Ý¼°Óâ34,000Ãû°©Ö¢»¼Õß¡£¸´ºêººÁØDZÐÄÉî¸û·Î°©ÖÎÁÆÁìÓò£¬Î§ÈÆHÒ©¾ÙÐÐÁ˷ΰ©Ò»ÏßÖÎÁƵÄÖÜÈ«½á¹¹£¬³ýÒÑ»ñÅúÉÏÊеÄsqNSCLC¡¢ES-SCLCÍ⣬ÆÕ±éÁýÕÖ·ÇÁÛ×´·ÇСϸ°û·Î°©£¨nsqNSCLC£©¡¢¾ÖÏÞÆÚСϸ°û·Î°©£¨LS-SCLC£©µÈ˳Ӧ֢£¬¿ÉÍû»Ý¼°Áè¼Ý90%µÄ·Î°©»¼Õß¡£
Õ¹ÍûδÀ´£¬¸´ºêººÁØÒ²½«¼ÌÐøÒÔ»¼ÕßÐèÇóΪ½¹µã£¬ÒÀ¸½¸ßЧ¼°Á¢ÒìµÄ×ÔÖ÷½¹µãÄÜÁ¦Ò»Á¬Íƽø¸ü¶àººÁØ¡°ÖÊ¡±Ô죬ΪȫÇò»¼ÕßÌṩ¸ßÆ·ÖʵÄÒ©ÎïºÍЧÀÍ¡£
¹ØÓÚIASLC WCLC
¹ØÓÚHÒ©
¹ØÓÚ¸´ºêººÁØ
Henlius Announces Upcoming Oral Presentation at WCLC 2023 Featuring?Results for HANSIZHUANG from a Phase 3 MRCT in sqNSCLC
From September 9-12, 2023, the IASLC 2023 World Conference on Lung Cancer (¡°WCLC 2023¡±) hosted by the International Association for the Study of Lung Cancer will be held in Singapore. Results of the final analysis of efficacy, including progression-free survival (PFS) and overall survival (OS), and safety from the pivotal ASTRUM-004 study of HANSIZHUANG (serplulimab) plus chemotherapy as first-line treatment for previously untreated locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC) will be orally presented by the leading principal investigator of ASTRUM-004, Professor Caicun Zhou from Shanghai Pulmonary Hospital.
ASTRUM-004 is a randomized, double-blind, international multicenter phase 3 study to compare the clinical efficacy and safety of serplulimab plus chemotherapy versus chemotherapy in patients with locally advanced or metastatic sqNSCLC who have not previously received systemic treatment. The study was conducted in various countries, including China, Poland, and Turkey, and enrolled 537 patients. Current data showed that serplulimab significantly improved survival with a manageable safety profile in previously untreated locally advanced or metastatic sqNSCLC patients. Previously in 2022, the new drug application (NDA) of serplulimab for the treatment of sqNSCLC has been approved by the National Medical Products Administration (NMPA) based on the results of ASTRUM-004.
HANSIZHUANG is Henlius¡¯ first innovative product, as well as the first and only anti-PD-1 therapy approved for the treatment of small cell lung cancer (SCLC). Since its launch in March 2022, it has been approved for 3 indications in China including MSI-H solid tumours, sqNSCLC and extensive-stage small cell lung cancer (ES-SCLC), benefitting over 34,000 patients in China. Henlius has devoted itself to lung cancer and built a comprehensive layout of the first-line treatment for lung cancer in sqNSCLC, ES-SCLC, nonsquamous non-small cell lung cancer (nsNSCLC) and limited-stage small cell lung cancer (LS-SCLC), which covers more than 90% of lung cancer patients.
In the future, Henlius will keep focusing on patient needs and inspire more "made-by-Henlius" products with efficient and innovative in-house capabilities, aiming to provide higher quality solutions and services for patients worldwide.
About IASLC WCLC
About HANSIZHUANG
About Henlius
µã»÷Á´½Ó¿É»ñÈ¡ÍêÕûÕªÒª